About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

IMO Declares A Cancer Care Crisis in the U.S.

The state of cancer care is in crisis and getting worse.  There is an ever growing demand for cancer care, a shrinking workforce, rising healthcare costs and an increasing complexity of treatment of cancer.  According to the Institute of Medicine (IMO) cancer care in America is in a deep crisis! In analysing the current state [...]

Knowing When Zytiga and Xtandi Have Failed Even Though The PSA Is Not Consistent With Disease Progression?

On the advanced prostate cancer online support group there have been some questions raised about how we know when drugs like Zytiga and Xtandi have stopped working. Knowing this as soon as possible is important so that you can quickly move on to the next treatment without giving the prostate cancer time to progress and [...]

Criteria and One’s Experience with Hospice Care

Someone on the advanced prostate cancer online support group ask about what are the criteria to go into hospice care. One individual replied that you would need to be within 6 months of your potential death. Another person replied from their individual experience. They said, “Hospice in CT doesn’t have a life expectancy strictly attached [...]

Provenge is Approved to Market in the European Union

It was announced today by Dendreon Corp. that the European Commission (EC) has granted marketing authorization for Provenge in the European Union (EU) for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. This final decision by the EC follows [...]

Dr. Francis Collins (NIH) Speaks About the Cancer Funding Predicament We Face

A post from Alan on the Advanced Prostate Cancer On-Line Support Group shared a link, which should interest all of us. It should interest us all because it will have an effect on each and every one of us, whether we are a prostate cancer survivor, if we become one in the future. Actually the [...]

Yervoy (ipilimumab) Fails to Extend Survival in Men with mCRP Who Failed Chemo

Some bad news was reported today. Results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in men with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel showed no increase in overall survival. Yervoy is an immunotherapy which [...]

Living Through Chemo with the Support of Natural Immune System Boosts – Probiotics

Mama might have been correct, eat your yogurt. Many of us already know that a healthy gut with plenty of probiotics to support your gastrointestinal health is absolutely critical to boosting your immune system. Experts say that gut flora could account for as much as 80% of our immune system! A study from the University [...]

Perineural Invasion – Is It An Accurate Predictor of Extra-Prostatic Extension of Prostate Cancer?

Many clinicians are concerned when a patient comes to them with prostate cancer that has been shown to have perineural invasion (PNI). PNI is defined as the presence of prostate cancer found by biopsy that tracks along or around a nerve within the perineural space. The presence of PNI has been a concern because of [...]

Who will respond to Zytiga (Abiraterone) and Xtandi (Enzalutamide)?

We have many new drugs that have been recently approved to treat advanced prostate cancer. Two of these drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). These drugs offer new hope to men with advanced prostate cancer after the cancer has become resistant to hormone therapies (called "castration-resistant prostate cancer"). These drugs are a real breakthrough, [...]

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

Go to Top